Compare FTRE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | NVCR |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2023 | 2015 |
| Metric | FTRE | NVCR |
|---|---|---|
| Price | $10.39 | $13.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $15.39 | ★ $28.08 |
| AVG Volume (30 Days) | 2.1M | ★ 2.8M |
| Earning Date | 05-25-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,723,400,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $2.96 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.00 | ★ 8.28 |
| 52 Week Low | $3.97 | $9.82 |
| 52 Week High | $18.67 | $21.55 |
| Indicator | FTRE | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 56.71 |
| Support Level | $9.35 | $12.66 |
| Resistance Level | $11.41 | $14.25 |
| Average True Range (ATR) | 1.01 | 1.19 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 57.60 | 58.28 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.